Treatment with ibudilast — an anti-inflammatory being developed to treat people with progressive forms of multiple sclerosis (MS) —…
Articles by Lindsey Shapiro, PhD
The U.S. Food and Drug Administration (FDA) has agreed to review Viatris and Mapi Pharma‘s application seeking approval…
For the first time, multiple sclerosis (MS) therapies have been added to the World Health Organization (WHO)’s Model…
Dawn Health, a Danish digital health company, has developed a smartphone app to support and empower people living with…
The risk of developing multiple sclerosis (MS) was similar between first- and second-degree family members of people with…
What a person eats in childhood can influence their future risk of developing multiple sclerosis (MS) and its clinical…
The presence of spinal cord lesions — alone or with brain lesions — on MRI scans was associated with a…
INmune Bio‘s experimental therapy XPro1595 may promote myelin restoration through the activation of two types of nervous system support…
Tysabri (natalizumab) is better than five other disease-modifying therapies (DMTs) at reducing relapses and preventing disability worsening in…
Adding optic nerve damage — reflected by a thinning of the nerve layer in the eye’s retina — to the…
Women with multiple sclerosis (MS) are three times more likely to face problems with sexual intimacy than are their…
Nerve cells coated with myelin — the fatty substance that’s lost in multiple sclerosis (MS) — may be…
Researchers have developed computer algorithms that may be able to predict certain aspects of cognitive change in multiple sclerosis…
Diet was found to significantly influence the severity of multiple sclerosis (MS) symptoms among patients living in Denmark in…
People with multiple sclerosis (MS) should generally follow a regular vaccination schedule similar to their healthy peers, with certain…
Ocrevus (ocrelizumab) — given by infusion — may work better than certain oral treatments to prevent relapses and disability…
Reductions in microglial activation have been observed in the brains of five of six patients with nonactive secondary progressive…
Physical disability, not whether patients are depressed, when they’re diagnosed with multiple sclerosis significantly influences their future disability progression,…
Frexalimab, an experimental anti-CD40L antibody therapy from Sanofi, significantly reduced the number of new brain lesions with active inflammation…
The National Multiple Sclerosis Society has awarded Clene Nanomedicine a grant to advance its treatment candidate CNM-Au8 for…
Vidofludimus calcium (IMU-838), an investigational multiple sclerosis (MS) therapy with promising results in clinical trials, may exert neuroprotective…
A more pro-inflammatory diet is associated with a higher risk of relapses and more inflammatory brain lesions for multiple…
Surgical procedures to treat trigeminal neuralgia — a type of nerve damage that causes facial pain — may be…
A four-month home-based aerobic walking program was feasible and may help improve cognitive function for multiple sclerosis (MS) patients,…
Tysabri (natalizumab) is generally safe and effectively lowers disease activity in people with multiple sclerosis (MS), according to…
Clusters of immunoglobulin G (IgG) antibodies in the blood of multiple sclerosis (MS) patients appear to contribute to the nerve…
About 2.5 years of treatment with tolebrutinib was associated with low relapse rates and stable disability levels among people…
Multiple sclerosis (MS) patients with greater psychological resilience — a better ability to cope with and recover quickly from…
OCH, a molecule designed to have beneficial effects on immune regulation in multiple sclerosis (MS), led to increases in…
OCS-05, a neuroprotective treatment candidate being developed by Oculis for multiple sclerosis (MS) or other causes of…